Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caris Life Sciences, Inc.CAI · Entity 3706 | Director | May 29, 2026 | June 02, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caris Life Sciences, Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,729 |
Reported balance
After 2026-05-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 1,600 · Balance 17,729 F1: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026. F2: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 511,702 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 511,702 F2: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.
F2: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.
EXELIXIS, INC.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,199 |
Reported balance
After 2026-05-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,367 · Balance 127,199 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.
F2: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MONSANTO CO /NEW/
Report date June 07, 2018 · Filed June 07, 2018
Section 16 reporting ended · disclosed 2018-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Payment Plan Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-07 · Disposition to issuer · Disposed 39,860 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration").
F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:44 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 1,600 | $15.62 | $24,992.00 |
DisclosureSEC source: 0001180770-26-000003 · wk-form4_1780436653.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,729 F1 · kind: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026. F2 · balance_after: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 8,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-26-000075 · wk-form4_1780090983.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,199 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| May 07, 2026 Filed May 8, 2026 23:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 60,000 | $45.71 | $2,742,600.00 |
DisclosureSEC source: 0000939767-26-000061 · wk-form4_1778281415.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,832 F1 · price: Represents the weighted average sales price. The shares of Exelixis, Inc. common stock ("Common Stock") were sold in multiple transactions at prices ranging from $45.65 to $45.85. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 9,812 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:07 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | Exercise / conversionStock Option · Derivative | 125,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001104659-25-077777 · tm2523446-3_4seq1.xml · derivative · entry 5 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2025-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:07 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | Tax withholdingCommon Stock | 91,495 | $29.75 | $2,721,976.25 |
DisclosureSEC source: 0001104659-25-077777 · tm2523446-3_4seq1.xml · nonDerivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,237 Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:07 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | Tax withholdingCommon Stock | 48,022 | $29.75 | $1,428,654.50 |
DisclosureSEC source: 0001104659-25-077777 · tm2523446-3_4seq1.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,732 Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:07 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | Exercise / conversionCommon Stock | 125,000 | $2.44 | $305,000.00 |
DisclosureSEC source: 0001104659-25-077777 · tm2523446-3_4seq1.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2025 Filed May 30, 2025 23:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000091 · wk-form4_1748646831.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,832 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 29, 2026, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 28,650 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-25-000083 · wk-form4_1747443499.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 20,634 shares of Common Stock, became fully exercisable on May 23, 2019. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,634 | $45.99 | $948,957.66 |
DisclosureSEC source: 0000939767-25-000083 · wk-form4_1747443499.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,020 F1 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,634 | $19.77 | $407,934.18 |
DisclosureSEC source: 0000939767-25-000083 · wk-form4_1747443499.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,874 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000939767-25-000026 · wk-form4_1740015121.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,874 shares Expires 2025-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,874 shares of Common Stock, became fully exercisable on May 24, 2018. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,874 | $34.74 | $551,462.76 |
DisclosureSEC source: 0000939767-25-000026 · wk-form4_1740015121.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,020 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.70 to $34.82. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,874 | $20.50 | $325,417.00 |
DisclosureSEC source: 0000939767-25-000026 · wk-form4_1740015121.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 30,000 | $34.00 | $1,020,000.00 |
DisclosureSEC source: 0000939767-24-000155 · wk-form4_1730851484.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,020 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $33.99 to $34.08. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 23:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 33,725 | $26.89 | $906,865.25 |
DisclosureSEC source: 0000939767-24-000127 · wk-form4_1723504947.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,020 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.86 to $26.96. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 18,838 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document |
| May 31, 2024 Filed Jun 5, 2024 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 18,838 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000101 · wk-form4_1717546855.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,745 F1 · date: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date. F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 39,556 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document |
| May 21, 2024 Filed May 22, 2024 23:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 11,686 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-24-000076 · wk-form4_1716420188.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,686 shares Expires 2024-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 11,686 shares of Exelixis, Inc. common stock, became fully exercisable on May 25, 2017. Read SEC document |
| May 21, 2024 Filed May 22, 2024 23:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 11,686 | $20.96 | $244,938.56 |
DisclosureSEC source: 0000939767-24-000076 · wk-form4_1716420188.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,907 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.95 to $20.99. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 21, 2024 Filed May 22, 2024 23:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 11,686 | $19.57 | $228,695.02 |
DisclosureSEC source: 0000939767-24-000076 · wk-form4_1716420188.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 01, 2023 Filed Jun 3, 2023 01:20 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 20,718 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000059 · wk-form4_1685755243.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,907 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on June 1, 2024, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 20,718 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000939767-22-000116 · wf-form4_166994345555782.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $16.68 | $667,200.00 |
DisclosureSEC source: 0000939767-22-000116 · wf-form4_166994345555782.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,189 Read SEC document |
| November 29, 2022 Filed Dec 2, 2022 01:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $6.30 | $252,000.00 |
DisclosureSEC source: 0000939767-22-000116 · wf-form4_166994345555782.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 26, 2022 Filed May 28, 2022 01:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 19,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000080 · wf-form4_165370096337874.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,189 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 26, 2023, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 19,575 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 27, 2021 Filed May 29, 2021 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 16,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000059 · wf-form4_162224717088166.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,614 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,802 | $24.97 | $1,018,825.94 |
DisclosureSEC source: 0000939767-21-000052 · wf-form4_162129669367535.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,190 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.94 to $25.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000939767-21-000025 · wf-form4_161421584386456.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2021-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $3.38 | $135,200.00 |
DisclosureSEC source: 0000939767-21-000025 · wf-form4_161421584386456.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 23:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 29,662 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0000939767-20-000120 · wf-form4_159744901922438.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,662 shares Expires 2020-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 59,662 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 23:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 29,662 | $5.82 | $172,632.84 |
DisclosureSEC source: 0000939767-20-000120 · wf-form4_159744901922438.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 21, 2020 Filed May 23, 2020 00:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 15,538 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000092 · wf-form4_159019528462136.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,330 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 21, 2021, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 25,855 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0000939767-20-000071 · wf-form4_158898677213589.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,662 Underlying: Common Stock · 30,000 shares Expires 2020-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 59,662 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 30,000 | $25.61 | $768,300.00 |
DisclosureSEC source: 0000939767-20-000071 · wf-form4_158898677213589.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,792 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.50 to $25.85. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $5.82 | $174,600.00 |
DisclosureSEC source: 0000939767-20-000071 · wf-form4_158898677213589.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 00:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000939767-19-000164 · wf-form4_156626027625737.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 00:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 25,000 | $20.50 | $512,500.00 |
DisclosureSEC source: 0000939767-19-000164 · wf-form4_156626027625737.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,792 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.50 to $20.51. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 00:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 25,000 | $4.58 | $114,500.00 |
DisclosureSEC source: 0000939767-19-000164 · wf-form4_156626027625737.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 23:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0000939767-19-000161 · wf-form4_156539491810179.xml · derivative · entry 5 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 23:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000939767-19-000161 · wf-form4_156539491810179.xml · derivative · entry 4 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 23:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $20.60 | $412,000.00 |
DisclosureSEC source: 0000939767-19-000161 · wf-form4_156539491810179.xml · nonDerivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,792 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.59 to $20.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 23:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $5.92 | $88,800.00 |
DisclosureSEC source: 0000939767-19-000161 · wf-form4_156539491810179.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 23:55 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 5,000 | $4.58 | $22,900.00 |
DisclosureSEC source: 0000939767-19-000161 · wf-form4_156539491810179.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000127 · wf-form4_155874402459385.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:27 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000127 · wf-form4_155874402459385.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,792 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:37 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000073 · wf-form4_155390261997027.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:37 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 3,860 | $23.89 | $92,215.40 |
DisclosureSEC source: 0000939767-19-000073 · wf-form4_155390261997027.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,475 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.66 to $24.00. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:37 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000073 · wf-form4_155390261997027.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 16:51 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | Disposition to issuerDeferred Payment Plan Restricted Stock Unit · Derivative | 39,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-015468 · doc4.xml · derivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,860 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.exercise_price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · derivative.exercise_date: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.exercise_date: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · derivative.expiration_date: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.expiration_date: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document |
| May 24, 2018 Filed May 25, 2018 00:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 15,874 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000109 · wf-form4_152720813374361.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,874 Underlying: Common Stock · 15,874 shares Expires 2025-05-23 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.